-
1
-
-
84927130807
-
Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential
-
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205-214 (2015).
-
(2015)
Cell
, vol.161
, Issue.2
, pp. 205-214
-
-
Sharma, P.1
Allison, J.P.2
-
2
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
3
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
4
-
-
84940890382
-
Big opportunities for small molecules in immuno-oncology
-
Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14(9), 603-622 (2015).
-
(2015)
Nat. Rev. Drug Discov.
, vol.14
, Issue.9
, pp. 603-622
-
-
Adams, J.L.1
Smothers, J.2
Srinivasan, R.3
Hoos, A.4
-
5
-
-
84880747672
-
Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance
-
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74-88 (2013).
-
(2013)
Immunity
, vol.39
, Issue.1
, pp. 74-88
-
-
Zitvogel, L.1
Galluzzi, L.2
Smyth, M.J.3
Kroemer, G.4
-
6
-
-
84937846973
-
Evolving synergistic combinations of targeted immunotherapies to combat cancer
-
Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15(8), 457-472 (2015).
-
(2015)
Nat. Rev. Cancer
, vol.15
, Issue.8
, pp. 457-472
-
-
Melero, I.1
Berman, D.M.2
Aznar, M.A.3
Korman, A.J.4
Perez Gracia, J.L.5
Haanen, J.6
-
7
-
-
84862769116
-
An immune-active tumor microenvironment favors clinical response to ipilimumab
-
Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61(7), 1019-1031 (2012).
-
(2012)
Cancer Immunol. Immunother.
, vol.61
, Issue.7
, pp. 1019-1031
-
-
Ji, R.R.1
Chasalow, S.D.2
Wang, L.3
-
8
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014).
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
-
9
-
-
84969545536
-
HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma
-
(Epub ahead of print)
-
Zheng H, Zhao W, Yan C et al. HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-15-2584 (2016) (Epub ahead of print).
-
(2016)
Clin. Cancer Res.
-
-
Zheng, H.1
Zhao, W.2
Yan, C.3
-
10
-
-
84878602787
-
Lung tumor NFkappaB signaling promotes T cell-mediated immune surveillance
-
Hopewell EL, Zhao W, Fulp WJ et al. Lung tumor NFkappaB signaling promotes T cell-mediated immune surveillance. J. Clin. Invest. 123(6), 2509-2522 (2013).
-
(2013)
J. Clin. Invest.
, vol.123
, Issue.6
, pp. 2509-2522
-
-
Hopewell, E.L.1
Zhao, W.2
Fulp, W.J.3
-
11
-
-
84882267461
-
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer
-
Ma T, Galimberti F, Erkmen CP et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol. Cancer Ther. 12(8), 1545-1555 (2013).
-
(2013)
Mol. Cancer Ther.
, vol.12
, Issue.8
, pp. 1545-1555
-
-
Ma, T.1
Galimberti, F.2
Erkmen, C.P.3
-
12
-
-
84879657918
-
Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4
-
Burke SJ, Goff MR, Lu D, Proud D, Karlstad MD, Collier JJ. Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4. J. Immunol. 191(1), 323-336 (2013).
-
(2013)
J. Immunol.
, vol.191
, Issue.1
, pp. 323-336
-
-
Burke, S.J.1
Goff, M.R.2
Lu, D.3
Proud, D.4
Karlstad, M.D.5
Collier, J.J.6
-
13
-
-
84905994658
-
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
-
Kim K, Skora AD, Li Z et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl Acad. Sci. USA 111(32), 11774-11779 (2014).
-
(2014)
Proc. Natl Acad. Sci. USA
, vol.111
, Issue.32
, pp. 11774-11779
-
-
Kim, K.1
Skora, A.D.2
Li, Z.3
-
14
-
-
72249084921
-
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824
-
Vo DD, Prins RM, Begley JL et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69(22), 8693-8699 (2009).
-
(2009)
Cancer Res.
, vol.69
, Issue.22
, pp. 8693-8699
-
-
Vo, D.D.1
Prins, R.M.2
Begley, J.L.3
-
15
-
-
79952760874
-
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
-
Christiansen AJ, West A, Banks KM et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc. Natl Acad. Sci. USA 108(10), 4141-4146 (2011).
-
(2011)
Proc. Natl Acad. Sci. USA
, vol.108
, Issue.10
, pp. 4141-4146
-
-
Christiansen, A.J.1
West, A.2
Banks, K.M.3
-
16
-
-
84891276397
-
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
-
West AC, Mattarollo SR, Shortt J et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 73(24), 7265-7276 (2013).
-
(2013)
Cancer Res.
, vol.73
, Issue.24
, pp. 7265-7276
-
-
West, A.C.1
Mattarollo, S.R.2
Shortt, J.3
-
17
-
-
84892942381
-
New and emerging HDAC inhibitors for cancer treatment
-
West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124(1), 30-39 (2014).
-
(2014)
J. Clin. Invest.
, vol.124
, Issue.1
, pp. 30-39
-
-
West, A.C.1
Johnstone, R.W.2
-
18
-
-
84946912433
-
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
-
Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249-253 (2015).
-
(2015)
Nature
, vol.527
, Issue.7577
, pp. 249-253
-
-
Peng, D.1
Kryczek, I.2
Nagarsheth, N.3
-
19
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568-571 (2014).
-
(2014)
Nature
, vol.515
, Issue.7528
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
-
20
-
-
84975063521
-
Differential association of STK11 and TP53 with KRAS mutationassociated gene expression, proliferation and immune surveillance in lung adenocarcinoma
-
(Epub ahead of print)
-
Schabath MB, Welsh EA, Fulp WJ et al. Differential association of STK11 and TP53 with KRAS mutationassociated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene doi:10.1038/onc.2015.375 (2015) (Epub ahead of print).
-
(2015)
Oncogene
-
-
Schabath, M.B.1
Welsh, E.A.2
Fulp, W.J.3
|